title: [Immunotherapy for unresectable pancreatic cancer].
abstract: To treat unresectable pancreatic cancer, we have performed cell therapies using lymphokine-activated killer cell, cytotoxic T lymphocytes (CTLs) induced by mixed lymphocyte culture (MLC) with autologous tumor cells, and CTL recognizing MUC1 induced by MLC with an allogeneic pancreatic tumor cells line, YPK-1. CTL therapy was effective in some cases. We also performed cell therapy using MUC1 peptide-pulsed dendritic cells (MUC1-DCs) and MUC1-CTLs. This therapy was effective in one of three cases so far. Cancer peptide vaccine therapy trials for unresectable pancreatic cancer are also ongoing. Cell therapy and peptide vaccine therapy may be promising approaches for unresectable pancreatic cancer.
authors.affiliation: Dept. of Digestive Surgery and Surgical Oncology (Surgery II), Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
authors.forename: Noboru
authors.initials: N
authors.lastname: Yahara
authors.forename: Masaaki
authors.initials: M
authors.lastname: Oka
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000096:biosynthesis; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010446:Peptide Fragments / Q000096:biosynthesis; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation*
chemical_list: C116055:MUC1 tandem repeat peptide; D018396:Mucin-1; D010446:Peptide Fragments